Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventActive Not Recruiting
NCT07000123Phase 3Updated Aug 11, 2026
Sponsor: AstraZeneca
Cardiovascular Disease
United States, Argentina, Australia, Brazil, Bulgaria +17 more
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 DiabetesCompleted
NCT06340854Phase 3Updated Aug 11, 2026
Sponsor: Novo Nordisk A/S
Diabetes, Type 2
United States, Bulgaria, Germany, India, Japan +4 more
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for PainRecruiting
NCT01719055N/AUpdated Aug 11, 2026
Sponsor: Boston Scientific Corporation
Pain
United States, Argentina, Australia, Belgium, Canada +11 more
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Recruiting
NCT06263231Phase 3Updated Aug 11, 2026
Sponsor: Intensity Therapeutics, Inc.
Sarcoma,Soft Tissue
United States, Canada, France, Germany, Spain
Global Patient Registry of Inherited Retinal DiseasesCompleted
NCT05957276N/AUpdated Aug 11, 2026
Sponsor: Janssen Research & Development, LLC
Inherited Retinal Diseases
United States, Australia, Austria, Belgium, Brazil +13 more
Study of the Effectiveness of VRET Combined With tDCS in the Treatment of PTSD in Ukrainian Veterans and CiviliansRecruiting
NCT06806267NAUpdated Aug 11, 2026
Sponsor: Malek Bajbouj
PTSD - Post Traumatic Stress Disorder
Germany
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPTerminated
NCT05581199Phase 2Updated Aug 11, 2026
Sponsor: Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
United States, Argentina, Belgium, Brazil, Bulgaria +16 more
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)Completed
NCT06920771Phase 3Updated Aug 10, 2026
Sponsor: HAL Allergy
House Dust Mite Allergy · House Dust Mite Rhinitis
Bulgaria, Germany, Latvia, Lithuania, Poland
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Recruiting
NCT07361510Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Austria, Belgium +31 more
A Study in Patients With Chronic Obstructive Pulmonary DiseaseCompleted
NCT01245569Phase 3Updated Aug 10, 2026
Sponsor: Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Denmark, France, Germany, Hungary, Italy +5 more
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive Not Recruiting
NCT06298552Phase 3Updated Aug 10, 2026
Sponsor: argenx
Generalized Myasthenia Gravis · gMG · Myasthenia Gravis, Generalized · Myasthenia Gravis
United States, Belgium, Canada, China, Cyprus +17 more
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)Active Not Recruiting
NCT05134012Phase 3Updated Aug 10, 2026
Sponsor: MedTrace Pharma A/S
Coronary Artery Disease
United States, Canada, Denmark, Germany, Netherlands +1 more
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaActive Not Recruiting
NCT05805501Phase 2Updated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Renal Cell Carcinoma
United States, Australia, China, France, Germany +4 more
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Recruiting
NCT06926868Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +23 more
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)Active Not Recruiting
NCT06128564Phase 2Updated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Duchenne Muscular Dystrophy
Belgium, France, Germany, Italy, Spain +1 more
A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are ToleratedCompleted
NCT06429137Phase 1Updated Aug 10, 2026
Sponsor: Boehringer Ingelheim
Healthy
Germany
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruiting
NCT07063745Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
United States, Argentina, Australia, Austria, Belgium +29 more
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseActive Not Recruiting
NCT06401044Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Amgen
Thyroid Eye Disease
United States, Australia, Canada, France, Germany +7 more
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or ObesityNot Yet Recruiting
NCT07754474Phase 1Updated Aug 10, 2026
Sponsor: Boehringer Ingelheim
Overweight · Obesity
Germany
PULSTA TPV Observational StudyNot Yet Recruiting
NCT07747207N/AUpdated Aug 10, 2026
Sponsor: Taewoong Medical Co., Ltd.
Heart Disease
Germany, Italy, Poland, South Korea, Spain +1 more
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Completed
NCT05153239Phase 3Updated Aug 10, 2026
Sponsor: PharmaMar
Relapsed Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive Not Recruiting
NCT01892722Phase 3Updated Aug 10, 2026
Sponsor: Novartis Pharmaceuticals
Multiple Sclerosis
United States, Australia, Austria, Brazil, Bulgaria +20 more
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruiting
NCT07100106Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Genentech, Inc.
Breast Cancer
United States, Australia, Brazil, Canada, China +5 more
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryActive Not Recruiting
NCT06161441Phase 2Updated Aug 10, 2026
Sponsor: Regeneron Pharmaceuticals
Resectable Non-small Cell Lung Cancer
United States, Australia, Chile, France, Georgia +7 more
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling By Invitation
NCT06926621Phase 2Updated Aug 10, 2026
Sponsor: Vertex Pharmaceuticals Incorporated
Myotonic Dystrophy Type 1 (DM1)
United States, Australia, Belgium, Canada, Germany +3 more

Previous page Next page